Sinovac Biotech, Ltd.: valuation

SVANASDAQHealthcare · Pharmaceutical Preparations

Price

$6.47

November 12, 2026Market cap $465M

DCF calculator

What Ploutos Investor adds for Sinovac Biotech

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • A figure that did not match the numbers it is built from has been left out.

Valuation today

What the market pays for the company's earnings, cash flow, book value and revenue at $6.47 (November 12, 2026), beside the median of its past fiscal years.

EV / EBIT
–
EV / Revenue
–
Earnings yield
–
FCF yield
–
Market cap
$465M
enterprise value –

DCF calculator

What is Sinovac Biotech worth on your own assumptions?

The DCF calculator opens with the company's figures already filled in from its filings. You set how fast its cash flow grows and the return you ask for, and see the value those assumptions give.

Free cash flow, 12 months
-$561M
Net cash
$5.5B
Shares
71.86M
FCF, 5-year average a year
–
Revenue, 5-year average a year
-5.4%
Price
$6.47
Value SVA

The full analysis

What do Sinovac Biotech's filings show?

The multiples say what the market pays for Sinovac Biotech. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about SVA's valuation

Didn't find what you were looking for?

Ask us
How do I work out what SVA is worth?

With the DCF calculator: it opens with Sinovac Biotech's figures from its filings, you enter your assumptions for growth and the return you ask for, and see the value they give. The company pages give no price target of their own. A full analysis gives a fair-value range, which is an estimate, not a target.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

US stocksThe market today, the sectors, the largest companies and the week's results.The market's sectorsThe 11 sectors side by side: returns, share of the market, median P/E and dividend.Compare stocksTwo companies side by side: price over up to ten years, with and without dividends, and every figure.US dividend stocksEach dividend's yield next to whether the company's cash covers it and whether it was ever cut.

The figures come from the company's SEC filings and the share price, and describe what it has reported. The estimated fair value, where shown, is our estimate, labelled as one: not a fact, not a score and not a recommendation to buy or sell.